We analyzed the outcomes of 74 patients diagnosed with BCR-ABL− myeloproliferative
neoplasms in blast phase receiving induction chemotherapy (55%), low-intensity therapy …

Oncogenic activation of tyrosine kinase signaling pathway is recurrent in human leukemia.
To gain insight into the oncogenic process leading to acute megakaryoblastic leukemia …

Optimal clinical management of patients with primary myelofibrosis and post-essential
thrombocythemia/polycythemia vera myelofibrosis is a challenge, given the typically …

Post–polycythemia vera myelofibrosis (post-PV MF) is a late evolution of PV. In 647 patients
with PV, we found that leukocytosis leukocyte count>(15× 109/L) at diagnosis is a risk factor …

BACKGROUND. Previous prognostic studies in primary myelofibrosis have focused on risk
factors for overall survival and have resulted in the establishment of several prognostic …

The frequency of cytogenetic abnormalities in the Philadelphia-negative myeloproliferative
neoplasms (MPNs) varies from approximately 30% in primary myelofibrosis (PMF) to less …

Familial chronic myeloproliferative disorders are defined when in the same pedigree at least
two relatives have a chronic myeloproliferative disorder (CMD) as polycythemia vera (PV) …

Primary central nervous system leukemia presenting with an isolated oculomotor palsy -
ScienceDirect Skip to main contentSkip to article Elsevier logo Journals & Books Search …

The association of PRCA and myelofibrosis is very rare with only two such cases reported in
the literature. Leukemic transformation in myelofibrosis is known but the progression of …

The classical myeloproliferative disorders (MPDs) of essential thrombocythemia,
polycythemia vera, and primary myelofibrosis have an increasing predisposition to transform …